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Indoleamine 2,3-dioxygenase (IDO) is induced by proinflammatory cytokines and by CTLA-4-expressing T
cells and constitutes an important mediator of peripheral immune tolerance. In chronic hepatitis C, we found
upregulation of IDO expression in the liver and an increased serum kynurenine/tryptophan ratio (a reflection
of IDO activity). Huh7 cells supporting hepatitis C virus (HCV) replication expressed higher levels of IDO
mRNA than noninfected cells when stimulated with gamma interferon or when cocultured with activated T
cells. In infected chimpanzees, hepatic IDO expression decreased in animals that cured the infection, while it
remained high in those that progressed to chronicity. For both patients and chimpanzees, hepatic expression
of IDO and CTLA-4 correlated directly. Induction of IDO may dampen T-cell reactivity to viral antigens in
chronic HCV infection.
Indoleamine 2,3-dioxygenase (IDO) mediates conversion of
tryptophan to catabolites collectively known as kynurenines
(22). This enzyme is expressed by both epithelial and dendritic
cells induced by proinflammatory cytokines, including gamma
interferon (IFN-) and tumor necrosis factor alpha (20, 25).
Also, engagement of CTLA-4 with CD80/CD86 on the mem-
brane of dendritic cells stimulates IDO transcriptional expres-
sion and activity (4, 9, 19). Increased IDO activity provokes
tolerogenicity of antigen-presenting cells and deprives T cells
of tryptophan, leading to proliferation arrest and T-cell apop-
tosis (15). Kynurenine, on the other hand, has been shown to
act as an immunoregulatory molecule that mediates immuno-
suppressive effects in the tissue microenvironment (7, 22, 26).
IDO activity contributes to maternal tolerance in pregnancy
(21), control of allograft rejection (9), and protection against
autoimmunity (8).
Chronic infection caused by hepatitis C virus (HCV) is char-
acterized by weak T-cell responses, recognizing very few
epitopes. In contrast, viral clearance after acute infection or
after interferon therapy is associated with the presence of a
robust and polyclonal T-cell reaction (2, 3, 6, 10, 14, 18, 23, 24).
Thus, HCV has developed efficient means to escape T-cell
immunity, thus causing a high rate of chronic infections. The
molecular mechanisms that are responsible for immune toler-
ance to HCV antigens remains ill understood. Since IDO ac-
tivity may dampen T-cell reactivity and can contribute to
tolerogenicity of dendritic cells (17), we have analyzed IDO
expression by quantitative real-time PCR using -actin gene
expression as an endogenous control (12, 13) (IDO sense
primer, TGGCACACGCTATGGAAAAC; antisense, ATGC
ATCCCAGAACTAGACG; -actin sense primer, AGCCTC
GCCTTTGCCGA; antisense, CTGGTGCCTGGGGCG) in
liver samples from patients with chronic hepatitis C (CHC),
subjects with sustained virological response (SVR) after inter-
feron therapy, and patients with other forms of chronic liver
inflammation (chronic hepatitis B and steatohepatitis) and in
normal liver samples (Table 1, cohort 1). IDO mRNA levels
were significantly higher in the CHC group than in the other
groups. Patients with other forms of liver disease had values
higher than those for normal livers but lower than the CHC
values (Fig. 1A). Subjects with SVR showed values similar to
those for controls.
As an index of IDO activity, we measured the serum kynure-
nine/tryptophan ratio (KTR) for equivalent groups of patients
and for healthy controls (Table 1, cohort 2). KTR was deter-
mined by high-performance liquid chromatography (27). We
found that KTR was significantly higher for the CHC group
than for the other groups, which did not show significant dif-
ferences among them (Fig. 1B). Since both IDO mRNA levels
and serum KTRs are significantly higher for CHC than in other
forms of liver disease (see Fig. 1A and B), it seems possible
that HCV might be especially efficient at facilitating IDO over-
expression in an inflamed milieu.
To determine whether HCV replication may enhance IDO
expression in response to proinflammatory cytokines, we
stimulated with IFN- (100 U/ml; R&D Systems, Minneap-
olis, MN), for 16, 24, and 40 h, Huh7 cells containing the
full-length HCV replicon (Huh7-Core-3) (12, 16), Huh7
cells producing JFH1-HCV viral particles (28), and control
cells. JFH1-Huh7 cells were used at 30 to 35 days postin-
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fection, when about 50 to 60% of cells were positive for the
HCV core protein, as determined by immunofluorescence.
As shown in Fig. 2A and B, both Huh7-Core-3 cells and Huh7
cells producing JFH1 generated increased amounts of IDO
mRNA in response to IFN- at all time points compared to
control Huh7 cells. These findings indicate that HCV replication
sensitizes the cells to produce IDO at high levels in response to
IFN-, a proinflammatory cytokine that is upregulated in the
livers of patients with CHC (1). IDO upregulation in response to
IFN- does not affect the replicative activity of HCV in the in-
fected cells, since treatment of the cells with IFN- plus an IDO
inhibitor (1-methyl tryptophan) or plus kynurenine did not pro-
voke changes in HCV-RNA levels in the infected cells with re-
spect to those observed with treatment of the cells with IFN-
alone (data not shown). It seems, therefore, that IDO upregula-
tion may represent a strategy of HCV to escape T-cell immunity
rather than a mechanism directly influencing HCV replication.
Our data suggest that one of the strategies used by HCV to
FIG. 1. IDO and HCV infection. (A) Real-time PCR quantitation of IDO mRNA in liver samples from normal livers, from patients with
chronic hepatitis C (CHC), from patients with CHC who cleared the virus after interferon therapy (SVR), or from a miscellaneous group of
patients with liver disorders unrelated to HCV. Results are normalized with -actin. (B) Kynurenine/tryptophan ratio in serum samples from
individuals belonging to groups equivalent to those shown in panel A. Statistical analyses were performed using nonparametric Kruskal-Wallis and
Mann-Whitney U tests. ns, not significant.
TABLE 1. Characteristics of patient cohorts
Variablea
Value for patient group
Normal
liver
Chronic
hepatitis C
Sustained virological
response
Miscellaneous
liver diseases
Amt of aspartate aminotransferase (IU/liter)
Cohort 1 14.7  5 42.1  28 10.8  2 35.4  24
Cohort 2 46.2  28.3 13.8  5 67.0  55
Amt of alanine aminotransferase (IU/liter)
Cohort 1 19.3  9 78.8  74 10.7  2 53.1  31
Cohort 2 36.5  17.9 15.4  5 50.3  44.5
Viral load (mean, IU/ml)
Cohort 1 6.5  107 0
Cohort 2 1.1  108 0
No. of samples with viral genotype (1/non-1/not determined)
Cohort 1 15/5/4
Cohort 2 12/4/3
Liver biopsy (Knodel’s score) inflammatory activity
Cohort 1 4.8  1.8 2.3  1.0 5.6  2.5
Cohort 2 5.4  2.2 0.25  0.5 5.4  2.5
Fibrosis score
Cohort 1 0.5  0.8 0.5  0.5 1.5  1.5
Cohort 2 1.4  1.5 0.25  0.5 1.1  1.2
a Cohort 1, liver tissues from normal liver, n  13 (samples obtained at surgery of liver metastasis or cholelithiasis); miscellaneous liver diseases, n  23 (of whom
11 were chronic hepatitis B patients and 12 were steatohepatitis patients); chronic hepatitis C, n  24 (of whom 11 were naive and 13 were nonresponders to pegylated
IFN-2 plus ribavirin); sustained virological response, n  11. Cohort 2, serum samples from healthy subjects, n  14; miscellaneous liver diseases, n  17 (of whom
6 were chronic hepatitis B patients and 11 steatohepatitis patients); chronic hepatitis C, n  19 (of whom 7 were naive and 12 nonresponders to pegylated IFN-2 plus
ribavirin); sustained virological response, n  19. Miscellaneous liver diseases and chronic hepatitis C patients did not differ in terms of aspartate aminotransferase/
alanine aminotransferase levels and histological grading. The study was approved by the local ethical committee.
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resist immune attack is by promoting IDO expression when
infected hepatocytes interact with effector T cells producing
IFN-. To test this hypothesis, Huh7 cells infected with JFH1
and control Huh7 cells were cocultured with 1.2  105 CD4
CD25	 cells from a healthy subject (using the negative fraction
of the CD4CD25 Regulatory T Cell Isolation kit; Miltenyi
Biotec, Bergisch Gladbach, Germany) in the presence of the
Dynabeads CD3/CD28 T-cell expander (Dynal biotech, Oslo,
Norway) to activate T cells. After 1 day, the coculture was
collected and both IFN- mRNA and IDO mRNA were de-
termined by quantitative real-time PCR (IFN- sense primer,
CTCTGCATCGTTTTGGGTTC; antisense, GCGTTGGAC
ATTCAAGTCAG). As shown in Fig. 2C and D, the induction
of IFN- was similar in cocultures containing control and in-
fected Huh7 cells, but the expression of IDO was significantly
higher in HCV-infected cultures. Since IDO levels were about
100-fold higher in coculture experiments than in experiments
using exogenous IFN-, whether other factors apart from
IFN-, such as cell contact, might be involved in this high IDO
upregulation was studied. Thus, when supernatant from acti-
vated CD4 CD25	 T cells was added to infected or nonin-
fected Huh7 cells, differences in IDO upregulation were not
observed (data not shown). It appears, therefore, that IDO
induction is mainly facilitated by cell contact between infected
cells and activated T lymphocytes. Whether IDO induction in
livers with CHC takes place in infected hepatocytes and/or in
inflammatory mononuclear cells has not been analyzed in the
present work. However, our data for HCV-infected hepatoma
cells suggest that hepatocytes are at least partially responsible
for the elevated hepatic levels of IDO found in CHC.
There is an intricate cross talk between IDO and CTLA-4
(17). It has been shown that tryptophan depletion together
with the presence of kynurenines promotes the expression of
inhibitory molecules, such as CTLA-4 and Foxp3, in T cells (5).
On the other hand, CTLA-4 stimulates IDO expression and
IDO activity in antigen-presenting cells, inducing tolerogenic
dendritic cells (17). Thus, we investigated whether IDO expres-
sion in the liver might correlate with the abundance of CTLA-4
mRNA in this organ. By using quantitative real-time PCR
(CTLA-4 sense primer, TCATGTACCCACCGCCATAC; an-
tisense, TAGACCCCTGTTGTAAGAGG), we found that
CTLA-4 mRNA levels were increased in liver biopsy samples
from HCV-infected patients over those in normal hepatic tis-
sue or in samples from patients with SVR or other forms of
liver disease (Fig. 3A). A significant direct correlation was
found between IDO mRNA levels and CTLA-4 mRNA levels
in liver tissue from HCV-infected patients (r  0.52; P 
 0.01)
(Fig. 3B).
Liver biopsies are not routinely performed for patients with
acute hepatitis C. Thus, in order to investigate the role of
hepatic IDO expression in the evolution of HCV infection, we
analyzed serial liver biopsy samples obtained from six chim-
panzees after they were infected with 25 50% chimpanzee
infectious doses of the HCV 1b J4 virus stock (Robert H.
Purcell, NIAID, NIH, Bethesda, MD). This study was ap-
proved by independent ethical committees in accordance with
international regulations (International Animal Care and Use
Committee). As shown in Fig. 3C, hepatic IDO mRNA de-
clined after an initial peak and remained low during evolution
in animals that cleared the virus, while in the chimpanzees that
evolved to chronicity, the initial peak of IDO expression was
lower but the levels remained elevated during evolution. Thus,
both in chimpanzees and in humans, chronic HCV infection is
associated with persistently high IDO expression in the liver.
An initial short-lived upregulation of IDO in the animals that
cleared the virus might be secondary to the induction of a
potent and efficient immune response. In fact, an early and
transient upsurge of IDO might take place in association with
activation of dendritic cells and T-cell immunity (11), while
persistent IDO overexpression may favor tolerance (17). Our
findings for acute infection in chimpanzees lend support to this
contention.
In parallel to IDO results, for chimps that cured the infec-
tion, CTLA-4 expression in the liver showed an initial peak and
then remained stable at very low levels during the evolution of
the disease (Fig. 3D). In contrast, for chimps that became
chronic carriers, expression of CTLA-4 showed little change
during the early phase of infection but tended to persist above
basal values along the course of the infection (Fig. 3D). As
with humans, we found a significant direct correlation between
IDO and CTLA-4 mRNA values in the liver (Fig. 3E).
In summary, we show upregulation of IDO in the livers of
patients and chimpanzees with chronic hepatitis C. This finding
is associated, and correlates, with overexpression of CTLA-4 in
liver tissue. Our data indicate that HCV infection facilitates
FIG. 2. Induction of IDO mRNA expression by HCV replication.
Quantitation of IDO mRNA levels by real-time PCR in Huh7 cells
with or without HCV replicon (Huh7-Core-3) (A) or JFH1 virus (B),
treated with 100 U/ml of IFN- for 0, 16, 24, or 40 h. Results are
expressed as the mean  standard deviations of one representative
experiment out of three experiments performed in sextuplicate. (C and
D) IDO and IFN- mRNA levels measured by real-time PCR in CD4
CD25	 cells cocultured for 1 day with Huh7 cells with or without HCV-
JFH1 in the presence of Dynabeads CD3/CD28 T-cell expander. All
results are normalized with -actin. Statistical analyses were performed
using the nonparametric Mann-Whitney U test. (*, P 
 0.01; Huh7-core
3 versus Huh7 or Huh7 plus JFH1 versus Huh7). ns, not significant.
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the induction of IDO in response to proinflammatory cyto-
kines and activated T cells. This may constitute an efficient
strategy of the virus to escape T-cell immunity. Our findings
point to novel targets for therapeutic intervention.
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FIG. 3. CTLA-4 and HCV infection. (A) Real-time PCR quantitation of CTLA-4 mRNA in samples from normal livers or from livers from
patients with CHC, from patients with CHC who cleared the virus after interferon therapy (SVR), or from a miscellaneous group of patients with
liver disorders unrelated to HCV. Statistical analyses were performed using nonparametric Kruskal-Wallis and Mann-Whitney U tests. ns, not
significant. (B) Correlation between mRNA levels of IDO and CTLA-4 in liver samples from CHC patients. (C and D) Real-time PCR quantitation
of IDO and CTLA-4 mRNA levels in liver samples from chimpanzees obtained at different time points before and after infection with infective
HCV inocula, with 0 being the week of infection. Solid lines, chimpanzees who cleared HCV infection; dotted lines, chimpanzees who did not clear
HCV infection. (E) Correlation between mRNA levels of IDO and CTLA-4 in liver samples from the chimpanzees described above. Results in
panels A, C, and D are normalized with -actin.
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